Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hemophilia A | 13 | 2020 | 362 | 4.96 | Why? |
| ABO Blood-Group System | 6 | 2021 | 995 | 2.31 | Why? |
| Factor VIII | 7 | 2020 | 229 | 1.96 | Why? |
| Tranexamic Acid | 3 | 2018 | 121 | 1.95 | Why? |
| Hemostatics | 6 | 2018 | 142 | 1.92 | Why? |
| Hemophilia B | 3 | 2020 | 45 | 1.68 | Why? |
| Isoantibodies | 3 | 2018 | 134 | 1.46 | Why? |
| Blood Loss, Surgical | 3 | 2018 | 211 | 1.41 | Why? |
| Immunization, Passive | 20 | 2021 | 10067 | 1.38 | Why? |
| von Willebrand Diseases | 2 | 2017 | 81 | 1.24 | Why? |
| Hemorrhage | 6 | 2020 | 3013 | 1.12 | Why? |
| Blood Coagulation Disorders | 4 | 2020 | 2040 | 0.91 | Why? |
| Agglutinins | 1 | 2021 | 15 | 0.91 | Why? |
| Anemia | 3 | 2018 | 789 | 0.91 | Why? |
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 63 | 0.87 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 2 | 2021 | 284 | 0.86 | Why? |
| Factor VIIa | 2 | 2012 | 27 | 0.84 | Why? |
| Antibodies, Neutralizing | 9 | 2021 | 25288 | 0.79 | Why? |
| Antibodies, Bispecific | 2 | 2020 | 207 | 0.78 | Why? |
| Hemostasis | 2 | 2017 | 811 | 0.78 | Why? |
| Tennis Elbow | 1 | 2018 | 6 | 0.77 | Why? |
| Fasciitis, Plantar | 1 | 2018 | 8 | 0.77 | Why? |
| Thrombocytopenia | 3 | 2021 | 2093 | 0.77 | Why? |
| Blood Transfusion | 6 | 2020 | 1399 | 0.75 | Why? |
| Thrombosis | 6 | 2021 | 7504 | 0.71 | Why? |
| Coagulants | 2 | 2017 | 30 | 0.71 | Why? |
| Platelet-Rich Plasma | 1 | 2018 | 91 | 0.70 | Why? |
| Plasmapheresis | 2 | 2020 | 437 | 0.68 | Why? |
| Anemia, Hemolytic | 1 | 2018 | 70 | 0.67 | Why? |
| Iron Chelating Agents | 1 | 2017 | 79 | 0.66 | Why? |
| Plasma | 3 | 2021 | 1809 | 0.62 | Why? |
| Blood Coagulation Disorders, Inherited | 2 | 2015 | 82 | 0.62 | Why? |
| Lipoprotein(a) | 1 | 2017 | 92 | 0.62 | Why? |
| Iron Overload | 1 | 2017 | 113 | 0.61 | Why? |
| Immune Sera | 1 | 2020 | 884 | 0.60 | Why? |
| Hemolysis | 1 | 2018 | 283 | 0.59 | Why? |
| Thalassemia | 1 | 2017 | 144 | 0.58 | Why? |
| Blood Coagulation Tests | 2 | 2017 | 855 | 0.56 | Why? |
| Transfusion Reaction | 1 | 2017 | 245 | 0.55 | Why? |
| Thrombophilia | 4 | 2020 | 1935 | 0.51 | Why? |
| Erythrocyte Transfusion | 1 | 2017 | 386 | 0.51 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2018 | 403 | 0.50 | Why? |
| Fibrinolysis | 1 | 2018 | 521 | 0.50 | Why? |
| Thrombelastography | 1 | 2018 | 627 | 0.47 | Why? |
| Hemoglobins | 1 | 2018 | 958 | 0.47 | Why? |
| Environment | 1 | 2018 | 769 | 0.46 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2018 | 669 | 0.45 | Why? |
| Antibodies, Viral | 9 | 2021 | 51949 | 0.45 | Why? |
| Blood Safety | 4 | 2021 | 459 | 0.44 | Why? |
| von Willebrand Factor | 1 | 2017 | 668 | 0.43 | Why? |
| Sports | 1 | 2018 | 690 | 0.42 | Why? |
| Venous Thromboembolism | 3 | 2018 | 4273 | 0.42 | Why? |
| Humans | 80 | 2021 | 930598 | 0.41 | Why? |
| Air Pollutants | 2 | 2018 | 3110 | 0.41 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.40 | Why? |
| Air Pollution | 2 | 2018 | 3504 | 0.38 | Why? |
| Blood Donors | 6 | 2021 | 2956 | 0.35 | Why? |
| Cesarean Section | 1 | 2018 | 2089 | 0.34 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.33 | Why? |
| Recombinant Proteins | 4 | 2017 | 3786 | 0.33 | Why? |
| Hemolytic-Uremic Syndrome | 1 | 2006 | 22 | 0.32 | Why? |
| Orthopedic Procedures | 1 | 2018 | 1231 | 0.32 | Why? |
| Fibrinogen | 3 | 2017 | 1048 | 0.32 | Why? |
| Venous Thrombosis | 1 | 2021 | 2739 | 0.30 | Why? |
| Postpartum Hemorrhage | 1 | 2007 | 144 | 0.29 | Why? |
| Donor Selection | 3 | 2021 | 804 | 0.29 | Why? |
| Blood Coagulation | 1 | 2018 | 2768 | 0.28 | Why? |
| Pregnancy Complications | 1 | 2016 | 1388 | 0.28 | Why? |
| Nephrotic Syndrome | 1 | 2007 | 146 | 0.28 | Why? |
| Randomized Controlled Trials as Topic | 6 | 2018 | 10649 | 0.27 | Why? |
| Coronavirus Infections | 10 | 2021 | 253789 | 0.26 | Why? |
| Purpura, Thrombocytopenic | 1 | 2003 | 12 | 0.26 | Why? |
| Multicenter Studies as Topic | 2 | 2021 | 2437 | 0.26 | Why? |
| Quality of Life | 3 | 2018 | 9820 | 0.24 | Why? |
| Antifibrinolytic Agents | 2 | 2018 | 150 | 0.24 | Why? |
| Blood Coagulation Factor Inhibitors | 2 | 2021 | 41 | 0.24 | Why? |
| Erythrocytes | 2 | 2018 | 617 | 0.23 | Why? |
| Anticoagulants | 3 | 2020 | 9563 | 0.22 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.22 | Why? |
| Thromboembolism | 2 | 2020 | 2101 | 0.22 | Why? |
| Factor IX | 1 | 2020 | 55 | 0.21 | Why? |
| Recurrence | 2 | 2021 | 3675 | 0.21 | Why? |
| Helicobacter Infections | 1 | 2003 | 216 | 0.20 | Why? |
| Helicobacter pylori | 1 | 2003 | 262 | 0.20 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.20 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.20 | Why? |
| Hemarthrosis | 1 | 2018 | 4 | 0.20 | Why? |
| Autoantibodies | 3 | 2021 | 2094 | 0.19 | Why? |
| Contraindications, Drug | 1 | 2020 | 281 | 0.19 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.19 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 1454 | 0.19 | Why? |
| Exercise | 1 | 2018 | 6771 | 0.18 | Why? |
| Upper Gastrointestinal Tract | 1 | 2018 | 61 | 0.17 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.17 | Why? |
| Disease Management | 3 | 2021 | 6841 | 0.17 | Why? |
| Benchmarking | 1 | 2021 | 627 | 0.16 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.16 | Why? |
| Patient Outcome Assessment | 1 | 2021 | 707 | 0.16 | Why? |
| Liver Diseases | 1 | 2012 | 2698 | 0.16 | Why? |
| Drug Substitution | 1 | 2020 | 385 | 0.16 | Why? |
| HELLP Syndrome | 1 | 2016 | 52 | 0.16 | Why? |
| PubMed | 1 | 2018 | 246 | 0.15 | Why? |
| Syndrome | 1 | 2021 | 1310 | 0.15 | Why? |
| Blood Component Transfusion | 1 | 2021 | 740 | 0.15 | Why? |
| Blood Preservation | 1 | 2017 | 191 | 0.15 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.15 | Why? |
| Plants | 1 | 2018 | 247 | 0.15 | Why? |
| Genetic Therapy | 1 | 2020 | 409 | 0.15 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.15 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.14 | Why? |
| Female | 20 | 2021 | 380317 | 0.14 | Why? |
| Professional-Patient Relations | 1 | 2020 | 426 | 0.14 | Why? |
| Pain Measurement | 1 | 2018 | 533 | 0.14 | Why? |
| Blood Banks | 2 | 2021 | 535 | 0.14 | Why? |
| Pregnancy | 5 | 2021 | 23879 | 0.14 | Why? |
| Technology | 1 | 2021 | 812 | 0.14 | Why? |
| Sinus Thrombosis, Intracranial | 1 | 2021 | 550 | 0.14 | Why? |
| Male | 18 | 2021 | 367725 | 0.13 | Why? |
| Chikungunya virus | 1 | 2017 | 339 | 0.13 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.13 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2017 | 801 | 0.13 | Why? |
| Fetal Blood | 1 | 2017 | 573 | 0.13 | Why? |
| Chikungunya Fever | 1 | 2017 | 345 | 0.13 | Why? |
| Cryopreservation | 1 | 2017 | 464 | 0.13 | Why? |
| Italy | 8 | 2021 | 38444 | 0.12 | Why? |
| Blood Chemical Analysis | 1 | 2017 | 541 | 0.12 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.12 | Why? |
| Blood Coagulation Factors | 2 | 2021 | 223 | 0.12 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.12 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.11 | Why? |
| Cost of Illness | 1 | 2021 | 1903 | 0.10 | Why? |
| Continuity of Patient Care | 1 | 2020 | 1574 | 0.10 | Why? |
| Chronic Pain | 1 | 2018 | 736 | 0.10 | Why? |
| Pre-Eclampsia | 1 | 2016 | 599 | 0.10 | Why? |
| Pain Management | 1 | 2018 | 854 | 0.10 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.10 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.09 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.09 | Why? |
| Fibrinolytic Agents | 1 | 2020 | 1702 | 0.09 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.09 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.09 | Why? |
| Adult | 10 | 2021 | 244371 | 0.09 | Why? |
| Pregnant Women | 1 | 2021 | 2535 | 0.09 | Why? |
| Child | 5 | 2021 | 70012 | 0.08 | Why? |
| Orthopedics | 1 | 2018 | 1279 | 0.08 | Why? |
| Health Resources | 1 | 2020 | 2592 | 0.08 | Why? |
| ADAM Proteins | 1 | 2006 | 43 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Databases, Factual | 1 | 2021 | 6248 | 0.08 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.08 | Why? |
| Particulate Matter | 1 | 2018 | 3249 | 0.07 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.07 | Why? |
| Animals | 4 | 2017 | 78931 | 0.07 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Uric Acid | 1 | 2008 | 285 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
| Hypoalbuminemia | 1 | 2007 | 235 | 0.07 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.07 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.07 | Why? |
| Case Management | 1 | 2006 | 285 | 0.07 | Why? |
| Proteinuria | 1 | 2007 | 474 | 0.06 | Why? |
| Fatty Liver | 1 | 2007 | 299 | 0.06 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.06 | Why? |
| Vulnerable Populations | 1 | 2017 | 3099 | 0.06 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.06 | Why? |
| Aged | 7 | 2021 | 215776 | 0.06 | Why? |
| Escherichia coli Infections | 1 | 2006 | 348 | 0.06 | Why? |
| ADAMTS13 Protein | 1 | 2006 | 363 | 0.06 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.06 | Why? |
| Economics, Pharmaceutical | 1 | 2021 | 61 | 0.05 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.05 | Why? |
| Alanine Transaminase | 1 | 2007 | 1329 | 0.05 | Why? |
| Fetal Monitoring | 1 | 2020 | 80 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Europe | 1 | 2017 | 12702 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.05 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2021 | 593 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Plasma Exchange | 1 | 2006 | 763 | 0.05 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.05 | Why? |
| Social Media | 1 | 2020 | 5798 | 0.05 | Why? |
| Registries | 1 | 2018 | 12327 | 0.04 | Why? |
| Infant | 1 | 2021 | 30274 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.04 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.04 | Why? |
| Trauma Severity Indices | 1 | 2017 | 176 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Imaging, Three-Dimensional | 1 | 2021 | 680 | 0.04 | Why? |
| Cardiovascular Diseases | 2 | 2018 | 11497 | 0.04 | Why? |
| Acute Coronary Syndrome | 1 | 2008 | 2107 | 0.03 | Why? |
| Extracellular Vesicles | 1 | 2021 | 607 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.03 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Blood Specimen Collection | 1 | 2017 | 387 | 0.03 | Why? |
| Aorta | 1 | 2016 | 355 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2017 | 694 | 0.03 | Why? |
| Public Health | 1 | 2018 | 16359 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| Monitoring, Physiologic | 1 | 2020 | 1956 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Polycystic Ovary Syndrome | 1 | 2009 | 151 | 0.02 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Incidence | 1 | 2007 | 25622 | 0.02 | Why? |
| Reference Values | 1 | 2007 | 795 | 0.02 | Why? |
| Troponin T | 1 | 2008 | 771 | 0.02 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.01 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2009 | 1380 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2007 | 9537 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |
Franchini's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(228)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(131)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_